BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, Mercuri E, Orazi L, SantaMaria M, Tremolada G, Santarsiero D, Waskowska A, Yashiro S, Denk N, Fürst-Recktenwald S, Gerber M, Gorni K, Jaber B, Jacobsen B, Mueller L, Nave S, Scalco RS, Marzoli SB; FIREFISH, SUNFISH, JEWELFISH Working Groups. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol 2021;8:54-65. [PMID: 33231373 DOI: 10.1002/acn3.51239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Klotz J, Tesi Rocha C, Dunaway Young S, Duong T, Buu M, Sampson J, Day JW. Advances in the Therapy of Spinal Muscular Atrophy. J Pediatr 2021;236:13-20.e1. [PMID: 34197889 DOI: 10.1016/j.jpeds.2021.06.033] [Reference Citation Analysis]
2 Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022;4:2. [PMID: 34983696 DOI: 10.1186/s42466-021-00162-9] [Reference Citation Analysis]
3 Eissa NR, Hassan HA, Senousy SM, Soliman HN, Essawi ML. SMA carrier testing using Real-time PCR as a potential preconception screening tool. Egypt J Med Hum Genet 2022;23. [DOI: 10.1186/s43042-022-00233-9] [Reference Citation Analysis]
4 Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2021;2:100346. [PMID: 34337562 DOI: 10.1016/j.xcrm.2021.100346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Banning A, Tikkanen R. Towards Splicing Therapy for Lysosomal Storage Disorders: Methylxanthines and Luteolin Ameliorate Splicing Defects in Aspartylglucosaminuria and Classic Late Infantile Neuronal Ceroid Lipofuscinosis. Cells 2021;10:2813. [PMID: 34831035 DOI: 10.3390/cells10112813] [Reference Citation Analysis]
6 Gaffar S, Cayabyab R, Ramanathan R. Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1? J Perinatol 2022. [PMID: 35095098 DOI: 10.1038/s41372-021-01301-5] [Reference Citation Analysis]
7 Markati T, Fisher G, Ramdas S, Servais L. Risdiplam: an investigational motor neuron-2 (SMN-2) splicing modifier for spinal muscular atrophy (SMA). Expert Opin Investig Drugs 2022. [PMID: 35316106 DOI: 10.1080/13543784.2022.2056836] [Reference Citation Analysis]
8 Sheikh O, Yokota T. Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy. BioDrugs 2021;35:389-99. [PMID: 34097287 DOI: 10.1007/s40259-021-00486-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]